Mounjaro KwikPen side effects: what to expect, what to watch for

The side effects most people actually experience

The body of evidence around tirzepatide (the active medicine in the Mounjaro KwikPen) shows a clear pattern. Gut-related effects are by far the most common, and they are strongly tied to dose transitions. Nausea, loose stools, constipation, indigestion, reflux and burping all appear in this category. Fatigue, headache and dizziness are also reported, particularly in the first couple of days after an injection.

For most people, these effects arrive after starting or after stepping up to a higher strength, then settle within one to two weeks as the body acclimates. Staying well hydrated, eating smaller meals and going slowly with fatty or spicy food during an adjustment period helps many people manage them. Injection-site redness or mild soreness is also possible; rotating between the abdomen, thigh and upper arm from one week to the next reduces this noticeably. A full guide to injection sites and how choice of site affects tolerability covers the practical detail.

The NHS medicines page for tirzepatide lists the full common and uncommon effects in plain language and is worth reading alongside the leaflet that comes with your pen.

When to get medical help straight away

Some reactions, though much less common, are serious and should not be waited out. Acute pancreatitis is one of them. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting it as an infrequent but potentially severe risk with GLP-1 medicines. The key symptom to know: severe, persistent stomach pain that radiates toward the back, with or without vomiting. If that happens, stop the injection and call 111 or go to A&E, do not manage it at home.

Other situations that need prompt medical attention include: signs of a serious allergic reaction (swelling of the face, lips, throat or tongue, difficulty breathing, rapid heartbeat); symptoms suggesting significant dehydration from prolonged vomiting or diarrhoea (dark urine, dizziness on standing, very little output); and gallbladder symptoms such as sudden pain in the upper right abdomen, fever or yellowing of the skin. These are not common, but knowing the signs matters.

There is also a question our prescribers hear fairly regularly about low mood or changes in mental state. The current evidence does not establish a direct causal link between tirzepatide and depression, but any new or worsening psychological symptoms are worth reporting to your doctor promptly. Our full side-effects guide for Mounjaro injections covers each of these categories in more depth.

Practical decisions: contraception, other medicines and surgery

Tirzepatide slows gastric emptying, which affects how quickly other medicines are absorbed. For women taking oral contraceptives, NHS guidance is specific: add a non-oral contraceptive method (condoms are the simplest) during the first four weeks of starting Mounjaro and for four weeks after each subsequent dose increase. This is the window when absorption of the pill may be reduced. There is not the same evidence of this effect for injectable semaglutide, but it applies clearly to tirzepatide.

Similarly, NHS England advises that women using oral hormone replacement therapy discuss moving to a transdermal format (patch or gel) with their doctor while on tirzepatide, for the same absorption reason. It is a conversation worth having before you start, not after.

If you are scheduled for any surgical or dental procedure requiring anaesthetic, tell the clinical team (including the anaesthetist) that you are taking tirzepatide. Slowed gastric emptying can affect anaesthesia safety, and your team needs that information. There are also practical notes about how to use and handle the KwikPen correctly that are worth reviewing, because improper injection technique occasionally causes local skin reactions that are avoidable. The pen should be stored refrigerated at 2–8°C; for precise guidance on how long it can be kept outside the fridge, the storage and fridge-life guidance page pulls together the key information.

Reporting side effects, and the Yellow Card scheme

Every person who experiences a suspected side effect from Mounjaro, or who thinks they have received a product that may not be genuine, can report it directly to the MHRA. The Yellow Card scheme accepts reports from patients as well as healthcare professionals. It takes around ten minutes online. These reports feed directly into ongoing safety monitoring and have contributed to updates like the January 2026 pancreatitis communication.

Tirzepatide carries a Black Triangle (▼) designation, meaning the MHRA actively collects additional safety data on it beyond the standard post-marketing requirement. That status reflects its relative newness, not a specific concern, it applies to many recently approved medicines. Reporting even mild effects that you are uncertain about helps build that evidence base.

At nume, our prescribers discuss your individual risk factors and medical history as part of every consultation. Side effects, what to do if they occur and when to call for help are all part of that review. If you have questions about whether Mounjaro is suitable for you, starting a free consultation is the first step. You can also read more about reported side effects across the Mounjaro injection range, or explore our full tirzepatide information hub if you are still at the research stage.